A fusion protein that combines IL-2v + PD-1 blockade reactivates exhausted immune cells in human lung cancer samples.
From @AlfredZippelius , @ClaraSerger , @DepBiomedicine , @UniBasel_en & University Hospital Basel, now in Phase I trials.
Paper in Science Translational Medicine.
https://t.co/wjcB2EpMcP
#Immunotherapy #CancerImmunology #FusionProtein